| 臺大學術典藏 |
2020-06-30T08:10:05Z |
Identification of Five Driver Gene Mutations in Patients with Treatment-Na?ve Lung Adenocarcinoma in Taiwan
|
Hsu K.-H.;Ho C.-C.;Hsia T.-C.;Tseng J.-S.;Kang-Yi Su;Wu M.-F.;Chiu K.-L.;Yang T.-Y.;Chen K.-C.;Ooi H.;Wu T.-C.;Chen H.-J.;Chen H.-Y.;Chang C.-S.;Hsu C.-P.;Hsia J.-Y.;Chuang C.-Y.;Lin C.-H.;Chen J.J.W.;Chen K.-Y.;Liao W.-Y.;Shih J.-Y.;Yu S.-L.;Yu C.-J.;Yang P.-C.;Chang G.-C.; Hsu K.-H.; Ho C.-C.; Hsia T.-C.; Tseng J.-S.; KANG-YI SU; Wu M.-F.; Chiu K.-L.; Yang T.-Y.; Chen K.-C.; Ooi H.; Wu T.-C.; Chen H.-J.; Chen H.-Y.; Chang C.-S.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Lin C.-H.; Chen J.J.W.; Chen K.-Y.; Liao W.-Y.; Shih J.-Y.; Yu S.-L.; Yu C.-J.; Yang P.-C.; Chang G.-C. |
| 臺大學術典藏 |
2020-06-30T08:10:03Z |
EGFR mutation and lobar location of lung adenocarcinoma
|
Tseng C.-H.;Chen K.-C.;Hsu K.-H.;Tseng J.-S.;Ho C.-C.;Hsia T.-C.;Kang-Yi Su;Wu M.-F.;Chiu K.-L.;Liu C.-M.;Wu T.-C.;Chen H.-J.;Chen H.-Y.;Chang C.-S.;Hsu C.-P.;Hsia J.-Y.;Chuang C.-Y.;Lin C.-H.;Chen J.J.W.;Chen K.-Y.;Liao W.-Y.;Shih J.-Y.;Yu S.-L.;Yu C.-J.;Yang P.-C.;Yang T.-Y.;Chang G.-C.; Tseng C.-H.; Chen K.-C.; Hsu K.-H.; Tseng J.-S.; Ho C.-C.; Hsia T.-C.; KANG-YI SU; Wu M.-F.; Chiu K.-L.; Liu C.-M.; Wu T.-C.; Chen H.-J.; Chen H.-Y.; Chang C.-S.; Hsu C.-P.; Hsia J.-Y.; Chuang C.-Y.; Lin C.-H.; Chen J.J.W.; Chen K.-Y.; Liao W.-Y.; Shih J.-Y.; Yu S.-L.; Yu C.-J.; Yang P.-C.; Yang T.-Y.; Chang G.-C. |
| 臺大學術典藏 |
2020-06-30T08:09:57Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.;Yang C.-Y.;Liao B.-C.;Ho C.-C.;Liao W.-Y.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Hsu W.-H.;Kang-Yi Su;Chang Y.-L.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.;Yu C.-J.; Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; KANG-YI SU; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2020-06-30T08:09:56Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.;Shih J.-Y.;Yu C.-J.;Ho C.-C.;Liao W.-Y.;Lee J.-H.;Tsai T.-H.;Kang-Yi Su;Hsieh M.-S.;Chang Y.-L.;Bai Y.-Y.;Huang D.D.-R.;Thress K.S.;Yang J.C.-H.; Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; Lee J.-H.; Tsai T.-H.; KANG-YI SU; Hsieh M.-S.; Chang Y.-L.; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-06-30T08:09:52Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Liu Y.-N.;Kang-Yi Su;Chang Y.-L.;Wu C.-T.;Liao B.-C.;Hsu C.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; KANG-YI SU; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-06-30T08:09:51Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Kang-Yi Su;Chang Y.-L.;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; KANG-YI SU; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-06-16T06:32:18Z |
Rapid atmospheric-pressure-plasma-jet processed porous materials for energy harvesting and storage devices
|
Chen, J.-Z.;Hsu, C.-C.;Wang, C.;Liao, W.-Y.;Wu, C.-H.;Wu, T.-J.;Liu, H.-W.;Chang, H.;Lien, S.-T.;Li, H.-C.;Hsu, C.-M.;Kao, P.-K.;Yang, Y.-J.;Cheng, I.-C.; Chen, J.-Z.; Hsu, C.-C.; Wang, C.; Liao, W.-Y.; Wu, C.-H.; Wu, T.-J.; Liu, H.-W.; Chang, H.; Lien, S.-T.; Li, H.-C.; Hsu, C.-M.; Kao, P.-K.; Yang, Y.-J.; Cheng, I.-C.; I-CHUN CHENG |
| 臺大學術典藏 |
2020-06-16T06:32:11Z |
Atmospheric-pressure-plasma-jet sintered dual-scale porous TiO2 using an economically favorable NaCl solution
|
Liao, W.-Y.;Yang, Y.-J.;Hsu, C.-M.;Hsu, C.-C.;Cheng, I.-C.;Chen, J.-Z.; Liao, W.-Y.; Yang, Y.-J.; Hsu, C.-M.; Hsu, C.-C.; Cheng, I.-C.; Chen, J.-Z.; I-CHUN CHENG |
| 臺大學術典藏 |
2020-06-16T06:32:08Z |
Oxygen-deficient indium tin oxide thin films annealed by atmospheric pressure plasma jets with/without air-quenching
|
Liao, W.-Y.;Chang, H.;Yang, Y.-J.;Hsu, C.-C.;Cheng, I.-C.;Chen, J.-Z.; Liao, W.-Y.; Chang, H.; Yang, Y.-J.; Hsu, C.-C.; Cheng, I.-C.; Chen, J.-Z.; I-CHUN CHENG |
| 臺大學術典藏 |
2020-05-26T09:27:09Z |
Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum
|
Yu C.-J.;Chen Y.-M;Chih-Hsin Yang;Cheng Y.-K;Chang G.-C;Shih J.-Y;Liao W.-Y; Liao W.-Y; Shih J.-Y; Chang G.-C; Cheng Y.-K; CHIH-HSIN YANG; Chen Y.-M; Yu C.-J. |
| 臺大學術典藏 |
2020-05-26T09:27:03Z |
Survival of lung adenocarcinoma patients with malignant pleural effusion
|
Wu S.-G;Yu C.-J;Tsai M.-F;Liao W.-Y;Chih-Hsin Yang;Jan I.-S;Yang P.-C;Shih J.-Y.; Wu S.-G; Yu C.-J; Tsai M.-F; Liao W.-Y; CHIH-HSIN YANG; Jan I.-S; Yang P.-C; Shih J.-Y. |
| 臺大學術典藏 |
2020-05-26T09:27:02Z |
Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer
|
Liao W.-Y;Chen J.-H;Wu M;Shih J.-Y;Chen K.-Y;Ho C.-C;Chih-Hsin Yang;Yu C.-J.; Liao W.-Y; Chen J.-H; Wu M; Shih J.-Y; Chen K.-Y; Ho C.-C; CHIH-HSIN YANG; Yu C.-J. |
| 臺大學術典藏 |
2020-05-26T09:27:00Z |
Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy
|
Tsai T.-H;Yang C.-Y;Ho C.-C;Liao W.-Y;Jan I.-S;Chen K.-Y;Wang J.-Y;Ruan S.-Y;Yu C.-J;Chih-Hsin Yang;Yang P.-C;Shih J.-Y.; Tsai T.-H; Yang C.-Y; Ho C.-C; Liao W.-Y; Jan I.-S; Chen K.-Y; Wang J.-Y; Ruan S.-Y; Yu C.-J; CHIH-HSIN YANG; Yang P.-C; Shih J.-Y. |
| 臺大學術典藏 |
2020-05-26T09:26:47Z |
Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis
|
Yang P.-C.;Rosell R;Chih-Hsin Yang;Yu C.-J;Shih J.-Y;Ho C.-C;Yu K.-L;Liao W.-Y;Su K.-Y;Ruan S.-Y;Molina-Vila M.A;Chen L.-Y; Chen L.-Y; Molina-Vila M.A; Ruan S.-Y; Su K.-Y; Liao W.-Y; Yu K.-L; Ho C.-C; Shih J.-Y; Yu C.-J; CHIH-HSIN YANG; Rosell R; Yang P.-C. |
| 臺大學術典藏 |
2020-05-26T09:26:39Z |
Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib
|
Shih J.-Y; Yu C.-J; Chih-Hsin CHIH-HSIN YANG; Lin C.-A; Liao W.-Y; Ho C.-C; Chih-Hsin Yang;Yu C.-J;Shih J.-Y;Lin C.-A;Liao W.-Y;Ho C.-C |
| 臺大學術典藏 |
2020-05-26T09:26:36Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Yu C.-J.;Chih-Hsin Yang;Lin C.-C;Lin Z.-Z;Chen J.-S;Shih J.-Y;Chen K.-Y;Ho C.-C;Liao W.-Y;Yao Z.-H; Yao Z.-H; Liao W.-Y; Ho C.-C; Chen K.-Y; Shih J.-Y; Chen J.-S; Lin Z.-Z; Lin C.-C; CHIH-HSIN YANG; Yu C.-J. |
| 臺大學術典藏 |
2020-05-26T09:26:34Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Yu C.-J.;Chih-Hsin Yang;Shih J.-Y;Lin C.-C;Lee J.-H;Chang Y.-L;Su K.-Y;Hsu W.-H;Hsu C.-L;Tsai T.-H;Chen K.-Y;Liao W.-Y;Ho C.-C;Liao B.-C;Yang C.-Y;Lin S.-Y; Lin S.-Y; Yang C.-Y; Liao B.-C; Ho C.-C; Liao W.-Y; Chen K.-Y; Tsai T.-H; Hsu C.-L; Hsu W.-H; Su K.-Y; Chang Y.-L; Lee J.-H; Lin C.-C; Shih J.-Y; CHIH-HSIN YANG; Yu C.-J. |
| 臺大學術典藏 |
2020-05-26T09:26:31Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Chih-Hsin Yang;Thress K.S;Huang D.D.-R;Bai Y.-Y;Chang Y.-L;Hsieh M.-S;Su K.-Y;Tsai T.-H;Lee J.-H;Liao W.-Y;Ho C.-C;Yu C.-J;Shih J.-Y;Lin C.-C; Lin C.-C; Shih J.-Y; Yu C.-J; Ho C.-C; Liao W.-Y; Lee J.-H; Tsai T.-H; Su K.-Y; Hsieh M.-S; Chang Y.-L; Bai Y.-Y; Huang D.D.-R; Thress K.S; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:28Z |
Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non?�Small-cell Lung Cancer Patients
|
Wu T.-H; Hsiue E.H.-C; Lee J.-H; Lin C.-C; Liao W.-Y; Ho C.-C; Shih J.-Y; Yu C.-J; CHIH-HSIN YANG; Chih-Hsin Yang;Yu C.-J;Shih J.-Y;Ho C.-C;Liao W.-Y;Lin C.-C;Lee J.-H;Hsiue E.H.-C;Wu T.-H |
| 臺大學術典藏 |
2020-05-26T09:26:24Z |
Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation?�Positive Advanced NSCLC: Findings From a Global Named Patient Use Program
|
Chang G.-C.;Cseh A;Carri?re P;Lorence R.M;Chih-Hsin Chih-Hsin Yang;Unk M;Spataro V;Gautschi O;Liao W.-Y;Shih J.-Y;Nechushtan H;Curioni-Fontecedro A;Peters S; Peters S; Curioni-Fontecedro A; Nechushtan H; Shih J.-Y; Liao W.-Y; Gautschi O; Spataro V; Unk M; Chih-Hsin CHIH-HSIN YANG; Lorence R.M; Carrière P; Cseh A; Chang G.-C. |
| 臺大學術典藏 |
2020-05-26T09:26:20Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Lin Y.-T;Chen J.-S;Liao W.-Y;Ho C.-C;Hsu C.-L;Yang C.-Y;Chen K.-Y;Lee J.-H;Lin Z.-Z;Shih J.-Y;Chih-Hsin Yang;Yu C.-J.; Lin Y.-T; Chen J.-S; Liao W.-Y; Ho C.-C; Hsu C.-L; Yang C.-Y; Chen K.-Y; Lee J.-H; Lin Z.-Z; Shih J.-Y; CHIH-HSIN YANG; Yu C.-J. |
| 臺大學術典藏 |
2020-05-26T09:26:19Z |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non?�small-cell lung cancer patients
|
Yao Z.-H;Liao W.-Y;Ho C.-C;Chen K.-Y;Shih J.-Y;Chen J.-S;Lin Z.-Z;Lin C.-C;Chih-Hsin Yang;Yu C.-J.; Yao Z.-H; Liao W.-Y; Ho C.-C; Chen K.-Y; Shih J.-Y; Chen J.-S; Lin Z.-Z; Lin C.-C; CHIH-HSIN YANG; Yu C.-J. |
| 臺大學術典藏 |
2020-05-26T09:26:18Z |
Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors
|
Lee J.-H;Chen H.-Y;Hsu F.-M;Chen J.-S;Liao W.-Y;Shih J.-Y;Yu C.-J;Chen K.-Y;Tsai T.-H;Chih-Hsin Yang; Lee J.-H; Chen H.-Y; Hsu F.-M; Chen J.-S; Liao W.-Y; Shih J.-Y; Yu C.-J; Chen K.-Y; Tsai T.-H; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:17Z |
Exon 16?�Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M?�Positive Non?�Small Cell Lung Cancer
|
Hsu C.-C;Liao B.-C;Liao W.-Y;Markovets A;Stetson D;Thress K;Chih-Hsin Yang; Hsu C.-C; Liao B.-C; Liao W.-Y; Markovets A; Stetson D; Thress K; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:17Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y;Liao W.-Y;Ho C.-C;Chen K.-Y;Tsai T.-H;Hsu C.-L;Su K.-Y;Chang Y.-L;Wu C.-T;Hsu C.-C;Liao B.-C;Hsu W.-H;Lee J.-H;Lin C.-C;Shih J.-Y;Chih-Hsin Yang;Yu C.-J.; Yang C.-Y; Liao W.-Y; Ho C.-C; Chen K.-Y; Tsai T.-H; Hsu C.-L; Su K.-Y; Chang Y.-L; Wu C.-T; Hsu C.-C; Liao B.-C; Hsu W.-H; Lee J.-H; Lin C.-C; Shih J.-Y; CHIH-HSIN YANG; Yu C.-J. |
| 臺大學術典藏 |
2020-05-25T07:35:15Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Ho C.-C; Chen K.-Y; Shih J.-Y; Chen J.-S; Lin Z.-Z; Chia-Chi Lin; Yang J.C.H; Yu C.-J.; Yao Z.-H; Liao W.-Y |
| 臺大學術典藏 |
2020-05-25T07:35:13Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Chia-Chi Lin; Shih J.-Y; Yu C.-J; Ho C.-C; Liao W.-Y; Lee J.-H; Tsai T.-H; Su K.-Y; Hsieh M.-S; Chang Y.-L; Bai Y.-Y; Huang D.D.-R; Thress K.S; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:13Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y; Yang C.-Y; Liao B.-C; Ho C.-C; Liao W.-Y; Chen K.-Y; Tsai T.-H; Hsu C.-L; Hsu W.-H; Su K.-Y; Chang Y.-L; Lee J.-H; Chia-Chi Lin; Shih J.-Y; Yang J.C; Yu C.-J. |
| 臺大學術典藏 |
2020-05-25T07:35:11Z |
Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non�VSmall-cell Lung Cancer Patients
|
Wu T.-H; Hsiue E.H.-C; Lee J.-H; Chia-Chi Lin; Liao W.-Y; Ho C.-C; Shih J.-Y; Yu C.-J; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:05Z |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non�Vsmall-cell lung cancer patients
|
Yu C.-J.;Yang J.C.-H;Chia-Chi Lin;Lin Z.-Z;Chen J.-S;Shih J.-Y;Chen K.-Y;Ho C.-C;Liao W.-Y;Yao Z.-H; Yao Z.-H; Liao W.-Y; Ho C.-C; Chen K.-Y; Shih J.-Y; Chen J.-S; Lin Z.-Z; Chia-Chi Lin; Yang J.C.-H; Yu C.-J. |
| 臺大學術典藏 |
2020-05-25T07:35:03Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yu C.-J.; Yang J.C.-H; Shih J.-Y; Yang C.-Y; Liao W.-Y; Ho C.-C; Chen K.-Y; Tsai T.-H; Hsu C.-L; Liu Y.-N; Su K.-Y; Chang Y.-L; Wu C.-T; Liao B.-C; Hsu C.-C; Hsu W.-H; Lee J.-H; Chia-Chi Lin |
| 臺大學術典藏 |
2020-05-25T07:35:02Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y; Liao W.-Y; Ho C.-C; Chen K.-Y; Tsai T.-H; Hsu C.-L; Su K.-Y; Chang Y.-L; Wu C.-T; Hsu C.-C; Liao B.-C; Hsu W.-H; Lee J.-H; Chia-Chi Lin; Shih J.-Y; Yang J.C.-H; Yu C.-J. |
| 臺大學術典藏 |
2020-05-25T02:45:29Z |
Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery
|
Yang W.-C;Xiao F;Shih J.-Y;Ho C.-C;Chen Y.-F;Tseng H.-M;Chen K.-Y;Liao W.-Y;Yu C.-J;Yang J.C.-H;Kuo S.-H;Cheng J.C.-H;Yang P.-C;Feng-Ming Hsu; Yang W.-C; Xiao F; Shih J.-Y; Ho C.-C; Chen Y.-F; Tseng H.-M; Chen K.-Y; Liao W.-Y; Yu C.-J; Yang J.C.-H; Kuo S.-H; Cheng J.C.-H; Yang P.-C; Feng-Ming Hsu |
| 臺大學術典藏 |
2020-05-25T02:45:22Z |
Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors
|
Lee J.-H;Chen H.-Y;Feng-Ming Hsu;Chen J.-S;Liao W.-Y;Shih J.-Y;Yu C.-J;Chen K.-Y;Tsai T.-H;Yang J.C.-H.; Lee J.-H; Chen H.-Y; Feng-Ming Hsu; Chen J.-S; Liao W.-Y; Shih J.-Y; Yu C.-J; Chen K.-Y; Tsai T.-H; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-25T01:32:58Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
YEN-TING LIN; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-05-20T05:11:42Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Yu C.-J.;Yang J.C.-H.;Shih J.-Y.;Lin Z.-Z.;Lee J.-H.;Chen K.-Y.;Yang C.-Y.;Hsu C.-L.;Ho C.-C.;Liao W.-Y.;Chen J.-S.;YEN-TING LIN; YEN-TING LIN; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-04-27T08:45:08Z |
Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery
|
Yang W.-C.;Xiao F.;Shih J.-Y.;Ho C.-C.;Chen Y.-F.;Tseng H.-M.;Chen K.-Y.;Liao W.-Y.;Yu C.-J.;Yang J.C.-H.;Kuo S.-H.;Chia-Hsien Cheng;Yang P.-C.;Hsu F.-M.; Yang W.-C.; Xiao F.; Shih J.-Y.; Ho C.-C.; Chen Y.-F.; Tseng H.-M.; Chen K.-Y.; Liao W.-Y.; Yu C.-J.; Yang J.C.-H.; Kuo S.-H.; CHIA-HSIEN CHENG; Yang P.-C.; Hsu F.-M. |
| 臺大學術典藏 |
2020-03-30T08:50:53Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Shih J.-Y.; JIN-SHING CHEN; Lin Z.-Z.; Lin C.-C.; Yang J.C.H.; Yu C.-J.; Yao Z.-H.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Shih J.-Y.;Jin-Shing Chen;Lin Z.-Z.;Lin C.-C.;Yang J.C.H.;Yu C.-J.; Yao Z.-H.; Liao W.-Y.; Ho C.-C.; Chen K.-Y. |
| 臺大學術典藏 |
2020-03-30T08:50:44Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Yu C.-J.; Yang J.C.-H.; Shih J.-Y.; Lin Z.-Z.; Lee J.-H.; Chen K.-Y.; Yang C.-Y.; Hsu C.-L.; Ho C.-C.; Lin Y.-T.;Jin-Shing Chen;Liao W.-Y.;Ho C.-C.;Hsu C.-L.;Yang C.-Y.;Chen K.-Y.;Lee J.-H.;Lin Z.-Z.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Lin Y.-T.; JIN-SHING CHEN; Liao W.-Y. |
| 臺大學術典藏 |
2020-03-30T08:50:43Z |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients
|
Yang J.C.-H.; Yu C.-J.; Lin C.-C.; Shih J.-Y.; JIN-SHING CHEN; Lin Z.-Z.; Chen K.-Y.; Liao W.-Y.; Ho C.-C.; Yao Z.-H.; Yao Z.-H.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Shih J.-Y.;Jin-Shing Chen;Lin Z.-Z.;Lin C.-C.;Yang J.C.-H.;Yu C.-J. |
| 臺大學術典藏 |
2020-03-30T08:50:42Z |
Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors
|
Lee J.-H.;Chen H.-Y.;Hsu F.-M.;Jin-Shing Chen;Liao W.-Y.;Shih J.-Y.;Yu C.-J.;Chen K.-Y.;Tsai T.-H.;Yang J.C.-H.; Lee J.-H.; Chen H.-Y.; Hsu F.-M.; JIN-SHING CHEN; Liao W.-Y.; Shih J.-Y.; Yu C.-J.; Chen K.-Y.; Tsai T.-H.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-03-30T02:21:31Z |
Cigarette smoke extract enhances the invasion of lung cancer cells co-cultured with fibroblasts in 3D cellular spheroids
|
Pan H.-J.;Hsin-Han Hou;Hung Y.-C.;Liao W.-Y.;Yu C.-J.;Lee C.-H.; Pan H.-J.; HSIN-HAN HOU; Hung Y.-C.; Liao W.-Y.; Yu C.-J.; Lee C.-H. |
| 臺大學術典藏 |
2020-03-09T06:08:08Z |
Augmented renal clearance is associated with inadequate antibiotic pharmacokinetic/ pharmacodynamic target in Asian ICU population: a prospective observational study
|
Wu C.-C.;Tai C.-H.;Liao W.-Y.;Wang C.-C.;Kuo C.-H.;Shu-Wen Lin;Ku S.-C.; Wu C.-C.; Tai C.-H.; Liao W.-Y.; Wang C.-C.; Kuo C.-H.; SHU-WEN LIN; Ku S.-C. |
| 臺大學術典藏 |
2020-03-07T06:57:11Z |
US-guided transthoracic cutting biopsy for peripheral thoracic lesions less than 3 cm in diameter
|
Liao W.-Y.;Chen M.-Z.;Yih-Leong Chang;Wu H.-D.;Yu C.-J.;Kuo P.-H.;Yang P.-C.; Liao W.-Y.; Chen M.-Z.; YIH-LEONG CHANG; Wu H.-D.; Yu C.-J.; Kuo P.-H.; Yang P.-C. |
| 臺大學術典藏 |
2020-03-07T06:57:01Z |
The utility and limitation of thyroid transcription factor-1 protein in primary and metastatic pulmonary neoplasms
|
Yih-Leong Chang;Lee Y.-C.;Liao W.-Y.;Wu C.-T.; YIH-LEONG CHANG; Lee Y.-C.; Liao W.-Y.; Wu C.-T. |
| 臺大學術典藏 |
2020-03-07T06:56:12Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; Lee J.-H.; Tsai T.-H.; Su K.-Y.; Hsieh M.-S.; YIH-LEONG CHANG; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H.; Lin C.-C.;Shih J.-Y.;Yu C.-J.;Ho C.-C.;Liao W.-Y.;Lee J.-H.;Tsai T.-H.;Su K.-Y.;Hsieh M.-S.;Yih-Leong Chang;Bai Y.-Y.;Huang D.D.-R.;Thress K.S.;Yang J.C.-H. |
| 臺大學術典藏 |
2020-03-07T06:56:12Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.;Yang C.-Y.;Liao B.-C.;Ho C.-C.;Liao W.-Y.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Hsu W.-H.;Su K.-Y.;Yih-Leong Chang;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.;Yu C.-J.; Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; YIH-LEONG CHANG; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2020-03-07T06:56:09Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Su K.-Y.;Yih-Leong Chang;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; YIH-LEONG CHANG; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-03-06T05:26:52Z |
US-guided transthoracic cutting biopsy for peripheral thoracic lesions less than 3 cm in diameter
|
Liao W.-Y.; Chen M.-Z.; YIH-LEONG CHANG; Wu H.-D.; Yu C.-J.; Kuo P.-H.; Yang P.-C. |
| 臺大學術典藏 |
2020-03-06T05:26:44Z |
The utility and limitation of thyroid transcription factor-1 protein in primary and metastatic pulmonary neoplasms
|
YIH-LEONG CHANG; Lee Y.-C.; Liao W.-Y.; Wu C.-T. |
